Mustang Bio, Inc.
MBIO
$0.61
-$0.02-3.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.52% | -58.12% | -56.23% | -55.36% | -57.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.63% | -91.90% | -91.88% | -80.89% | -75.25% |
| Operating Income | 80.63% | 91.90% | 91.88% | 80.89% | 75.25% |
| Income Before Tax | 87.80% | 90.03% | 89.78% | 73.28% | 69.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.80% | 90.03% | 89.78% | 73.28% | 69.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.80% | 90.03% | 89.78% | 73.28% | 69.47% |
| EBIT | 80.63% | 91.90% | 91.88% | 80.89% | 75.25% |
| EBITDA | 79.82% | 91.96% | 92.02% | 81.29% | 75.68% |
| EPS Basic | 99.13% | 98.62% | 97.90% | 90.72% | 85.04% |
| Normalized Basic EPS | 98.97% | 99.72% | 98.61% | 94.00% | 87.68% |
| EPS Diluted | 99.13% | 98.62% | 97.90% | 90.72% | 85.04% |
| Normalized Diluted EPS | 98.97% | 99.72% | 98.61% | 94.00% | 87.68% |
| Average Basic Shares Outstanding | 704.45% | 799.37% | 749.66% | 591.81% | 254.00% |
| Average Diluted Shares Outstanding | 704.45% | 799.37% | 749.66% | 591.81% | 254.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |